Naproxen Sodium: The Superior Choice Over Dexketoprofen for Dental Pain and Inflammation Management
Abstract
The management of postoperative pain and inflammation following dental procedures, such as dental implants and root canal therapies, is essential to ensure patient comfort and optimal recovery. Nonsteroidal anti-inflammatory drugs (NSAIDs) like Naproxen Sodium and Dexketoprofen are widely utilized due to their effectiveness in controlling pain and inflammation by inhibiting cyclooxygenase (COX) enzymes. This review compares the pharmacological characteristics, onset of action, duration of analgesic effects, and safety profiles of Naproxen Sodium and Dexketoprofen in managing pain associated with dental treatments. Naproxen Sodium’s rapid onset of action (within 15 minutes) and prolonged duration (up to 13 hours) make it a superior choice for postoperative pain control, minimizing the need for frequent dosing. Dexketoprofen, while providing pain relief within 30 minutes, has a shorter duration of effect, requiring more frequent administration. Naproxen Sodium also demonstrates superior anti-inflammatory properties and safety profile make it the preferred first-line option over Dexketoprofen for managing pain and inflammation following dental procedures as evidenced by FDA recommendations. The review concludes that Naproxen Sodium offers a more balanced efficacy, safety, and sustained analgesia, making it a preferred NSAID for managing postoperative dental pain and inflammation over Dexketoprofen.
Keywords: Naproxen Sodium, Dexketoprofen, Dental Pain, cyclooxygenase (COX) enzymes
Keywords:
Naproxen Sodium, Dexketoprofen, Dental Pain, yclooxygenase (COX) enzymesDOI
https://doi.org/10.22270/jddt.v14i11.6831References
1. Katherine N Theken et al. Front Pharmacol. 2023 May 17:14:1199580. doi: 10.3389/fphar.2023.1199580. eCollection 2023 https://doi.org/10.3389/fphar.2023.1199580 PMid:37266144 PMCid:PMC10229806
2. Magdi Hanna & Jee Y. Moon. A review of dexketoprofen trometamol in acute pain, Current Medical Research and Opinion, 2019;35(2):189-202, https://doi.org/10.1080/03007995.2018.1457016 PMid:29569951
3. Jackson ID. Br. J. Anaesth. 2004 May;92(5):675-80. https://doi.org/10.1093/bja/aeh131 PMid:15033894
4. Alonso Carrasco-Labra et al. Evidence-based clinical practice guideline for the pharmacologic management of acute dental pain. J Am Dent Assoc, 2024;155(2):102-117.e9. https://doi.org/10.1016/j.adaj.2023.10.009 PMid:38325969 PMCid:PMC10919895
5. Huskisson EC, Engler C et al. Current Medical Research and Opinion, 7:7, 471-474, https://doi.org/10.1185/03007998109114286 PMid:7021072
6. Aslam M et al. J R Soc Health. 1992 Jun;112(3):135-6. https://doi.org/10.1177/146642409211200308 PMid:1629878
7. Joanna Kuczyńska et al. Biomed Pharmacother. 2022 May:149:112819. https://doi.org/10.1016/j.biopha.2022.112819 PMid:35299123
8. Cennet-Neslihan Eroglu et al. Med Oral Patol Oral Cir Bucal. 2014 Nov 1;19 (6):e622-7.
9. Kerstin Malmstrom et al. Clin J Pain 2004;20:147-155 https://doi.org/10.1097/00002508-200405000-00004 PMid:15100590
10. Suheyb Bilge et al. Turkiye Klinikleri J Dental Sci. 2022;28(3):502-10. https://doi.org/10.5336/dentalsci.2021-86763
11. Bruce M. Psaty et al. N Engl J Med. 2007 Jan 25;356(4):328-30. https://doi.org/10.1056/NEJMp068286 PMid:17251528
12. Nair AS. Indian J Palliat Care. 2019 Jan-Mar; 25(1): 164-165. https://doi.org/10.4103/IJPC.IJPC_215_18 PMid:31413472 PMCid:PMC6659541
13. Lanas A et al. Reumatol Clin. 2014 Mar-Apr;10(2):68-84. https://doi.org/10.1016/j.reuma.2013.10.004 PMid:24462644
14. Guthrie B et al. Kidney360. 2020 Nov 25; 1(11): 1189-1191. https://doi.org/10.34067/KID.0005112020 PMid:35372868 PMCid:PMC8815518
15. Hanna M, Moon JY, A review of dexketoprofen trometamol in acute pain, Current Medical Research and Opinion, 2019;35:2, 189-202, https://doi.org/10.1080/03007995.2018.1457016 PMid:29569951
16. Laine L et al. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage. 2003 Feb;25(2 Suppl):S32-40. https://doi.org/10.1016/S0885-3924(02)00629-2 PMid:12604155
17. Dexketoprofen Summary of Product Characteristics. https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0901-001-003_12042018145038.pdf
18. Bjørnsson GA et al. Journal of Clinical Pharmacology, 2003;43:849-858, https://doi.org/10.1177/0091270003255361 PMid:12953342
Published
Abstract Display: 33 
PDF Downloads: 31 PDF Downloads: 3 How to Cite
Issue
Section
Copyright (c) 2024 Barkin Berk
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.